

SEQUENCE LISTING

<110> KYOWA HAKKO KOGYO CO., LTD.

<120> Anaerobic bacterium as a drug for cancer gene therapy

5 <130> DK04F318(US)

<140>

<141>

<150> JP 00/287688

<151> 2000-9-21

10 <160> 3

<210> 1

<211> 600

<212> DNA

<213> Bifidobacterium longum

15 <220>

<221> CDS

<222> (193)..(471)

<400> 1

gctgggcgcg gcggccatga agtggcttga caagcataat ctgtctgat tegtctatit 60

20 tcaataccit cggggaaata gatgtgaaaa cctttataaa acgcgggtit tgcagaaac 120

atgcgctagt atcattgatg acaacatgga ctaagcaaaa gtgcttgtcc cctgacccaa 180

gaaggatgct tt atg gca tac aac aag tct gac ctc gtt tgc aag atc gcc 231

Met Ala Tyr Asn Lys Ser Asp Leu Val Ser Lys Ile Ala

1

5

10

25 cag aag tcc aac ctg acc aag gct cag gcc gag gct gct gtt aac gcc 279

Gln Lys Ser Asn Leu Thr Lys Ala Gln Ala Glu Ala Ala Val Asn Ala

15

20

25

ttc cag gat gtg ttc gtc gag gct atg aag tcc ggc gaa ggc ctg aag 327

Phe Gln Asp Val Phe Val Glu Ala Met Lys Ser Gly Glu Gly Leu Lys

5

30

35

40

45

ctc acc ggc ctg ttc tcc gct gag cgc gtc aag cgc ccg gct cgc acc 375

Leu Thr Gly Lue Phe Ser Ala Glu Arg Val Lys Arg Pro Ala Arg Thr

50

55

60

ggc cgc aac ccg cgc act ggc gag cag att gac att ccg gct tcc tac 423

10

Gly Arg Asn Pro Arg Thr Gly Glu Gln Ile Asp Ile Pro Ala Ser Tyr

65

70

75

ggc gtt cgt atc tcc gct ggc tcc ctg ctg aag aag gcc gtc acc gag 471

Gly Val Arg Ile Ser Ala Gly Ser Leu Leu Lys Lys Ala Val Thr Glu

80

85

90

15 tgaccitctg ctctgtagcga ttacttcgag cattactgac gacaaagacc ccgaccgaga 531

tggtcggggg ctttttgttg tgggtgctgtg acgtgttgic caaccgtatt attccggact 591

agttcagcg 600

<210> 2

<211> 18

20

<212> DNA

<213> Artificial sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 2

25

ggttcgaata acgcttta

18

$\langle 210 \rangle$ 3

<211> 23

<212> DNA

<213> Artificial sequence

5 $\langle 220 \rangle$

<223> Description of Artificial Sequence:synthetic DNA

$\langle 400 \rangle$ 3

cggttaactc aacgtttgta atc

23

10